 CAMBRIDGE, Mass.--BUSINESS WIRE--- AVRO--AVROBIO, Inc. NASDAQ: AVRO, a leading clinical-stage gene therapy company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of 15.00 per share. Gross proceeds from the underwritten public offering will total approximately 75 million, before deducting underwriting discounts and commissions and other offering expenses payable by the company. In addition, the company has granted 